home / stock / tcrr / tcrr news

TCRR News and Press, TCR2 Therapeutics Inc. From 05/14/20

Stock Information
Company Name: TCR2 Therapeutics Inc.
Stock Symbol: TCRR
Market: NYSE
Website: tcr2.com
Menu
TCRR TCRR Quote TCRR Short TCRR News TCRR Articles TCRR Message Board
Get TCRR Alerts

News, Short Squeeze, Breakout and More Instantly...
TCRR - TCR² Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Continued progress on treatment of TC-210 patients with interim update from Phase 1 portion of Phase 1/2 clinical trial anticipated in mid-2020 Continued progress of TC-110 with initiation of leading clinical sites participating in Phase 1/2 clinical trial that include Sarah Cannon Resea...
TCRR - TCR² Therapeutics Announces Veteran Finance Executive Stephen Webster Joins its Board of Directors

CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment of Stephen Webster to its Board of ...

TCRR - TCR² Therapeutics Announces Immuno-Oncology Pioneer Dr. Axel Hoos Joins its Board of Directors

CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment of Axel Hoos, M.D., Ph.D., to its...

TCRR - TCR² Therapeutics to Present at the Goldman Sachs Cell Therapy Day

CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Alfonso Quintás Cardama, M.D., Chief Me...
TCRR - TCR2 Therapeutics EPS beats by $0.14

TCR2 Therapeutics (NASDAQ: TCRR ): Q4 GAAP EPS of -$0.54 beats by $0.14 . Cash and cash equivalents of $65.3M Press Release More news on: TCR2 Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, ,

TCRR - TCR² Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Company initiated Phase 1/2 clinical trial for TC-110, its lead hematological malignancy candidate Interim update from Phase 1 portion of TC-210 Phase 1/2 trial anticipated in 2Q20 and Phase 1/2 trial of TC-110 in 2H20 TCR 2 manufacturing suite fully operational in Stevenage, United Ki...

TCRR - TCR² Therapeutics to Participate in Two Upcoming Conferences in February

CAMBRIDGE, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that management will participate in two upcoming c...
TCRR - TCR² Therapeutics to Present an Allogeneic Construct at the Keystone Symposia Conference on Emerging Cellular Therapies: Cancer and Beyond

CAMBRIDGE, Mass., Feb. 03, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will present a poster at the 2020 Keystone...

TCRR - Tcr2 Therapeutics (TCRR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

The following slide deck was published by TCR2 Therapeutics Inc. in conjunction with this Read more ...

TCRR - TCR² Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Garry Menzel, Ph.D., President and Chief Exec...
Previous 10 Next 10